Navigation Links
Pharmacopeia to Present at BIO CEO & Investor Conference 2008
Date:2/4/2008

PRINCETON, N.J., Feb. 4 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that Dr. Leslie J. Browne, President and Chief Executive Officer, will deliver a corporate presentation at the BIO CEO & Investor Conference 2008. The conference will be held February 11-13, 2008, at The Waldorf-Astoria Hotel in New York City.

Dr. Browne's presentation will take place at 2:00 p.m. EST on Tuesday, February 12th. The presentation will include an overview of the company's drug development pipeline, including an update on its internal clinical programs, PS433540 (DARA), which is progressing in Phase 2, and PS178990 (SARM), which is currently in Phase 1. A live webcast and 90-day archive of the presentation can be accessed at http://www.pharmacopeia.com.

ABOUT PHARMACOPEIA

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

Contact:

Amy P. Sharpless

Corpora
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
2. Pharmacopeia Announces Third Quarter 2007 Financial Results
3. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
4. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
5. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
6. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
9. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
10. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
11. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Leading events organizer UBM Live announces that CPhI ... São Paulo, Brazil from 5 th ... co-locate with Food Ingredients South America (FiSA), creating ... pharmaceutical industry.      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) Three ... exploring the South America market as ...
(Date:7/24/2014)... CITY, Calif. , July 24, 2014   ... specialty pharmaceutical company focused on the development and commercialization ... breakthrough pain, today confirmed the PDUFA date for Zalviso ... learned that a rumor circulated online stating the Food ... July 24, 2014 there has been no notification to ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Calif., Oct. 11 Threshold,Pharmaceuticals, Inc. (Nasdaq: THLD ... analysis, it would stop enrollment in a Phase 2 ... patients with,recurrent, sensitive small cell lung cancer. The ... there would be,an adequate response rate to justify complete ...
... KineMed Inc., a,pathway-based drug discovery and development company, ... an investigational agent,to regenerate nerve cells in the ... and mood. The agent, part of a partnered ... behavioral test in a,preclinical model. The findings were ...
Cached Medicine Technology:Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial 2Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial 3KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3
(Date:7/25/2014)... CMS recently has imposed a series ... inadequate access to prescription drugs. Agency audits are uncovering ... safety of beneficiaries in areas such as rejected pharmacy ... is taking quick and firm actions to halt them. ... “Avoiding Costly Part D Sanctions: Rx Access Strategies ...
(Date:7/25/2014)... Wa (PRWEB) July 25, 2014 ... Pdf review recently updated by Vkool.com, this ... people how to treat some common types ... hemorrhoids and internal hemorrhoids ,     Young ... pregnancy with hemorrhoids ,     Very large ...
(Date:7/25/2014)... According to the Addict Him To You Pdf review ... that teaches women how to get the love of the ... review that this book consists of 4 parts, including:, ... commit yet (and what to do about it) , ... ,     Part 3: How to touch his heart deeply ...
(Date:7/25/2014)... Silver®Care , for the first time in ... that naturally kill oral bacteria and airborne bacteria from the ... toothbrush is the most common and important device in the ... is subject to constant contamination by bacteria found in the ... in the mouth than anywhere else in the human body, ...
(Date:7/24/2014)... July 25, 2014 iFitDress.com, a renowned ... new range of casual party dresses . According ... party gowns are now offered at discounted prices, up ... this morning until August 04. , Most of ... in the global market. They are popular for special ...
Breaking Medicine News(10 mins):Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 3Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 3Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 2Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2
... Aug. 31 A new report,issued by the ... payments are 67 percent lower than anesthesia payments,from ... Anesthetists (CRNAs) are essential to ensuring that America,s ... pain management, and other,needed healthcare services., "Medicare ...
... of us hope our minds stay sharp,and active as ... simple as going to,the gym. Doctor Gary Small, a ... and aging, says the key to staying sharp is ... this report from Radica at:, http://media.medialink.com/WebNR.aspx?story=33787 Registered ...
... BlueCross BlueShield of South,Carolina has created a new ... Jill Davis to vice president in charge of ... to CEO M. Edward Sellers and is,responsible for ... formalizing a corporate-wide executive development program. "We ...
... Aug. 31 Lutheran Senior Services,(LSS), a leading ... that they provide the highest quality care and ... has partnered with Silverchair,Learning Systems to provide superior ... employees, beginning in January 2008. "Lutheran Senior ...
... Ill., Aug. 31 Landauer, Inc. (NYSE:,LDR) announced today ... dividend of $0.475 per share for the fourth quarter ... 5, 2007, to shareholders,of record on September 14, 2007. ... of analytical services to determine,occupational and environmental radiation exposure. ...
... World Heart,Corporation (WorldHeart) (Nasdaq: WHRT , ... today announced the appointment of,Mr. David Pellone as ... Juelis, the departing CFO, will provide consulting services,through ... the transition and with certain,specific projects. Mr. ...
Cached Medicine News:Health News:GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care 2Health News:S.C. BlueCross Creates Corporate Planning Unit, Promotes Davis to Vice President 2Health News:Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education 2Health News:Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education 3Health News:WorldHeart Appoints David Pellone Chief Financial Officer 2
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With reinforced ...
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With reinforced nylon ...
Medicine Products: